

**UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF OHIO**

**JOHN STINE,**

*Plaintiff,*

Case No. \_\_\_\_\_

Judge \_\_\_\_\_

**JURY TRIAL DEMANDED**

v.

NOVO NORDISK A/S, NOVO NORDISK  
NORTH AMERICA OPERATIONS A/S,  
NOVO NORDISK US HOLDINGS INC.,  
NOVO NORDISK US COMMERCIAL  
HOLDINGS INC., NOVO NORDISK INC.,  
NOVO NORDISK RESEARCH CENTER  
SEATTLE, INC., NOVO NORDISK  
PHARMACEUTICAL INDUSTRIES LP, and  
EMISPHERE TECHNOLOGIES

*Defendants.*

**COMPLAINT AND DEMAND FOR JURY TRIAL**

-----

Plaintiff, JOHN STINE, by Plaintiff's attorneys, Johnson Becker, upon information and belief, at all times hereinafter mentioned, alleges as follows:

**JURISDICTION AND VENUE**

1. This Court has jurisdiction over this action pursuant to 28 U.S.C. § 1332, because the amount in controversy as to Plaintiff exceeds \$75,000.00, exclusive of interest and costs, and because Defendants are incorporated and have their principal places of business in states other than the state in which Plaintiff resides, which is Carroll county, Ohio.

2. This Court has personal jurisdiction over Defendants, consistent with the United States Constitution and Oh. Rev. Code. 2307.382 (Ohio's "long arm" statute), as Plaintiff's claims

arise out of Defendants' transaction of business and the tortious acts within the State of Ohio, and by virtue of Defendants' substantial, continuous, and systematic contacts with the State of Ohio unrelated to Plaintiff's claims.

### **NATURE OF THE CASE**

3. This is an action for damages suffered by Plaintiff, John Stine, who was severely injured as a result of Plaintiff's use of Rybelsus, an oral prescription medication, that are used to control blood sugar in adults with type 2 diabetes.

4. Rybelsus is also known as semaglutide. Rybelsus works by stimulating insulin production and reducing glucose production in the liver helping to lower blood sugar levels.

5. Rybelsus belongs to a class of drugs called GLP-1 receptor agonists ("GLP-1RAs").

6. Defendants acknowledge that gastrointestinal events are well known side effects of the GLP-1RA class of drugs.<sup>1</sup> However, Defendants have downplayed the severity of the gastrointestinal events caused by their GLP-1RAs, never, for example, warning of the risk of gastroparesis ("paralyzed stomach") and its sequelae.

7. Gastroparesis is a condition that affects normal muscle movement in the stomach. Ordinarily, strong muscular contractions propel food through the digestive tract. However, in a person suffering from gastroparesis, the stomach's motility is slowed down or does not work at all, preventing the stomach from emptying properly. Gastroparesis can interfere with normal digestion and cause nausea, vomiting (including vomiting of undigested food), abdominal pain, abdominal bloating, severe dehydration, a feeling of fullness after eating just a few bites,

---

<sup>1</sup> See, e.g., CT Jones, *Ozempic Users Report Stomach Paralysis from Weight Loss Drug: 'So Much Hell'*, Rolling Stone (July 25, 2023), available at <https://www.rollingstone.com/culture/culture-news/ozempic-stomach-paralysis-weight-loss-side-effects-1234794601> (visited on 9/26/23).

undigested food hardening and remaining in the stomach, acid reflux, changes in blood sugar levels, lack of appetite, weight loss, malnutrition, and a decreased quality of life. There is no cure for gastroparesis.<sup>2</sup>

**PARTY PLAINTIFF**

8. Plaintiff, John Stine, is a citizen of the United States, and is a resident of the State of Ohio.

9. Plaintiff is 46 years old.

10. Plaintiff used Rybelsus from March 15, 2022 to April 1, 2022.

11. Plaintiff's physician(s) ("prescribing physician(s)") prescribed the Rybelsus that was used by Plaintiff.

12. As a result of using Rybelsus, Plaintiff was caused to suffer from gastroparesis and, as a result, sustained severe and permanent personal injuries, pain, suffering, and emotional distress, and incurred medical expenses.

13. As a result of using Rybelsus, Plaintiff was caused to suffer from gastroparesis and its sequelae, which resulted in, for example, nausea, vomiting, and diarrhea.

**PARTY DEFENDANTS**

14. Defendant Novo Nordisk Inc. is a Delaware corporation with a principal place of business at 800 Scudders Mill Road, Plainsboro, New Jersey.

15. Upon information and belief, Defendant Novo Nordisk Inc. is wholly owned by Defendant Novo Nordisk US Commercial Holdings, Inc.

16. Upon information and belief, Defendant Novo Nordisk US Commercial Holdings Inc. is a Delaware corporation with a principal place of business at 103 Foulk Road, Wilmington,

---

<sup>2</sup> *Gastroparesis*, Mayo Clinic (June 11, 2022), available at <https://www.mayoclinic.org/diseases-conditions/gastroparesis/symptoms-causes/syc-20355787> (visited on 9/26/23).

Delaware.

17. Upon information and belief, Defendant Novo Nordisk US Commercial Holdings Inc. is wholly owned by Defendant Novo Nordisk US Holdings Inc.

18. Upon information and belief, Defendant Novo Nordisk US Holdings Inc. is a Delaware corporation with a principal place of business at 103 Foulk Road, Wilmington, Delaware.

19. Upon information and belief, Defendant Novo Nordisk US Holdings Inc. is wholly owned by Defendant Novo Nordisk A/S.

20. Defendant Novo Nordisk A/S is a public limited liability company organized under the laws of Denmark with a principal place of business in Bagsværd, Denmark.

21. Defendant Novo Nordisk North America Operations A/S is a company organized under the laws of Denmark with a principal place of business in Bagsværd, Denmark.

22. Novo Nordisk Research Center Seattle, Inc. is a Delaware corporation with a principal place of business at 530 Fairview Ave. N., Seattle, Washington.

23. Novo Nordisk Pharmaceutical Industries LP is a Delaware corporation with a principal place of business at 3611 and 3612 Powhatan Road, Clayton, North Carolina.

24. Defendant Novo Nordisk Pharmaceutical Industries LP is the labeler for Ozempic and Rybelsus, and Defendants Novo Nordisk A/S and Novo Nordisk Inc. are also identified on Ozempic's and Rybelsus's labels.<sup>3</sup>

25. Defendant Emisphere Technologies is a New Jersey corporation with a principal place of business at 4 Becker Farm Road, Roseland, New Jersey.

---

<sup>3</sup> Ozempic prescribing information, available at <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79> (visited on 9/26/23); Rybelsus prescribing information, available at <https://www.novo-pi.com/rybelsus.pdf> (last visited on 9/20/23).

26. Defendant Emisphere Technologies is a drug delivery company that develops oral formulations of therapeutic agents and developed the Eligen SNAC technology to translate drugs into oral form. Novo Nordisk A/S and/or its subsidiaries and/or affiliates used Eligen SNAC to develop its diabetes drug, Rybelsus.<sup>4</sup>

27. On November 6, 2020, Novo Nordisk A/S announced that it had agreed to a \$1.8 billion deal to acquire Emisphere Technologies.<sup>5</sup> The acquisition was completed on December 8, 2020.<sup>6</sup> Emisphere is now a subsidiary of Novo Nordisk A/S.

28. Defendants Novo Nordisk Inc., Novo Nordisk US Commercial Holdings Inc., Novo Nordisk US Holdings Inc., Novo Nordisk A/S, Novo Nordisk North America Operations A/S, Novo Nordisk Research Center Seattle, Inc., Novo Nordisk Pharmaceutical Industries LP, and Emisphere Technologies are referred to collectively herein as “Novo Nordisk.”

29. Novo Nordisk designed, researched, manufactured, tested, advertised, promoted, marketed, sold, and/or distributed Rybelsus. Alternatively, Novo Nordisk has acquired the entity/entities who designed, researched, manufactured, tested, advertised, promoted, marketed, sold, and distributed Rybelsus and is, thus, the successor to such entity/entities.

## **FACTUAL BACKGROUND**

### **A. FDA’s Approval of Ozempic**

30. On December 5, 2016, Novo Nordisk announced submission of a new drug application (NDA) to the FDA for regulatory approval of once-weekly injectable semaglutide, a

---

<sup>4</sup> Fraiser Kansteiner, *Novo Nordisk lays out \$1.8B for Emisphere and its oral delivery tech*, available at <https://www.fiercepharma.com/drug-delivery/novo-nordisk-tees-up-1-8b-emisphere-purchase-to-snare-oral-drug-delivery-tech> (last visited on 9/20/23).

<sup>5</sup> Novo Nordisk, *Novo Nordisk to acquire Emisphere Technologies and obtain ownership of the Eligen® SNAC oral delivery technology*, available at <https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=33374> (last visited on 9/20/23).

<sup>6</sup> Novo Nordisk, *Novo Nordisk announces completion of the Emisphere Technologies acquisition*, available at <https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=38064> (last visited on 9/20/23).

new glucagon-like peptide-1 (GLP-1) medication for treatment of type 2 diabetes. In the announcement, Novo Nordisk represented that in clinical trials “once-weekly semaglutide had a safe and well tolerated profile with the most common adverse event being nausea.”<sup>7</sup>

31. On December 5, 2016, Defendant Novo Nordisk Inc. submitted NDA 209637, requesting that the FDA grant it approval to market and sell Ozempic (semaglutide) 0.5 mg or 1 mg injection in the United States as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. On December 5, 2017, the FDA approved NDA 209637.<sup>8</sup>

32. On March 20, 2019, Defendant Novo Nordisk Inc. submitted supplemental new drug application (sNDA) 209637/S-003 for Ozempic (semaglutide) 0.5 mg or 1 mg injection, requesting approval to expand its marketing of Ozempic by adding an indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.<sup>9</sup> On January 16, 2020, the FDA approved sNDA 209637/S-003.<sup>10</sup>

33. On May 28, 2021, Defendant Novo Nordisk Inc. submitted sNDA 209637/S-009, requesting approval for a higher 2 mg dose of Ozempic (semaglutide) injection. On March 28, 2022, the FDA approved sNDA 209637/S-009.<sup>11</sup>

## **B. FDA’s Approval of Rybelsus**

34. On March 20, 2019, the Novo Nordisk Defendants announced the submission of a

---

<sup>7</sup> Novo Nordisk, *Novo Nordisk files for regulatory approval of once-weekly semaglutide in the US and EU for the treatment of type 2 diabetes* (Dec. 5, 2016), available at <https://ml.globenewswire.com/Resource/Download/d2f719e1-d69f-4918-ac7e-48fc6b731183> (visited on 9/26/23).

<sup>8</sup> FDA Approval Letter for NDA 209637 (Ozempic), available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/applletter/2017/209637s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2017/209637s000ltr.pdf) (visited on 9/26/23).

<sup>9</sup> *Novo Nordisk files for US FDA approval of oral semaglutide for blood sugar control and cardiovascular risk reduction in adults with type 2 diabetes*, Cision PR Newswire (March 20, 2019), available at <https://www.prnewswire.com/news-releases/novo-nordisk-files-for-us-fda-approval-of-oral-semaglutide-for-blood-sugar-control-and-cardiovascular-risk-reduction-in-adults-with-type-2-diabetes-300815668.html> (visited on 9/26/23).

<sup>10</sup> FDA Supplement Approval Letter for NDA 209637/A-003 (Ozempic), available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/applletter/2020/209637Orig1s003ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2020/209637Orig1s003ltr.pdf) (visited on 9/26/23).

<sup>11</sup> FDA Supplement Approval Letter for NDA 209637/S-009 (Ozempic), available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/applletter/2022/209637Orig1s009ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2022/209637Orig1s009ltr.pdf) (visited on 9/26/23).

new drug application (NDA) to the FDA for regulatory approval for oral semaglutide, under the brand name Rybelsus, the first once-daily glucagon-like peptide-1 receptor agonist for blood sugar control and cardiovascular risk reduction in adults with type 2 diabetes.<sup>12</sup>

35. On March 20, 2019, Defendant Novo Nordisk Inc. submitted NDA 213051, requesting that the FDA grant it approval to market and sell Rybelsus (oral semaglutide) in both 7 mg and 14 mg oral doses in the United States as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.<sup>13</sup> On September 20, 2019, the FDA approved NDA 213051.<sup>14</sup>

36. On December 10, 2019, Defendant Novo Nordisk Inc. submitted a supplemental new drug application (NDA 213051/S-001) for Rybelsus (semaglutide) asking “for the addition of efficacy and safety information to the prescribing information based on clinical data from the PIONEER 6 cardiovascular outcomes trial entitled, ‘A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.’”<sup>15</sup> On January 16, 2020, the FDA approved NDA 213051/S-001.<sup>16</sup>

37. On March 28, 2022, the FDA notified Defendant Novo Nordisk, Inc. of new safety information that it determined should be included in the labeling for GLP-1RA products pertaining to the risk of acute gallbladder disease. On April 27, 2022, Defendant Novo Nordisk, Inc.

---

<sup>12</sup> *Novo Nordisk files for US FDA approval of oral semaglutide for blood sugar control and cardiovascular risk reduction in adults with type 2 diabetes*, Cision PR Newswire (Mar. 20, 2019), available at <https://www.prnewswire.com/news-releases/novo-nordisk-files-for-us-fda-approval-of-oral-semaglutide-for-blood-sugar-control-and-cardiovascular-risk-reduction-in-adults-with-type-2-diabetes-300815668.html> (last visited on 9/20/23).

<sup>13</sup> Clinical Review for NDA 213051 (Rybelsus), available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2019/213051Orig1s000MedR.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213051Orig1s000MedR.pdf) (last visited on 9/22/23).

<sup>14</sup> FDA Approval Letter for NDA 213051 (Rybelsus), available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/applletter/2019/213051Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2019/213051Orig1s000ltr.pdf) (last visited on 9/20/23).

<sup>15</sup> FDA Approval Letter available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2020/213182Orig1s000Approv.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213182Orig1s000Approv.pdf) (last visited on 9/22/23).

<sup>16</sup> FDA Approval Letter for NDA 213051/S-001 (Rybelsus), available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/applletter/2020/213182Orig1s000,%20213051Orig1s001ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2020/213182Orig1s000,%20213051Orig1s001ltr.pdf) (last visited on 9/21/23).

submitted a supplemental new drug application (NDA 213051/S-011) and amendments for Rybelsus (semaglutide) tablets incorporating the FDA's required safety modifications to the label. On June 10, 2022, the FDA provided supplemental approval for NDA 213051/S-011.<sup>17</sup>

38. On July 15, 2022, Defendant Novo Nordisk Inc. submitted a supplemental new drug application (NDA 123051/S-012) for Rybelsus to remove the "Limitation of Use" statement "Not recommended as first-line therapy for patients inadequately controlled on diet and exercise" in the "Prescribing Information and Medication Guide" ("PI"). The following updates were also made to the PI information: a) addition of Pancreatitis and Diabetic Retinopathy Complications to the Other Adverse Reactions subsection in section 6.1, Clinical Trials Experience; b) updating the Immunogenicity section and moving it from section 6.2 to section 12.6; c) adding "Gastrointestinal: ileus" to section 6.2, Postmarketing Experience; d) revising section 7.1, Concomitant Use with an Insulin Secretagogue (e.g., Sulfonyleurea) or with insulin; and e) other minor grammatical changes. The FDA approved NDA 123051/S-012 on January 12, 2023.<sup>18</sup>

39. On January 12, 2023, the Novo Nordisk Defendants announced the FDA's approval of NDA 123051/S-012 for the label update described above. In the press release, the Novo Nordisk Defendants emphasized that "Rybelsus has been prescribed to hundreds of thousands of patients to help improve glycemic control[.]" and they disclosed Important Safety Information about Rybelsus and provided links to its Medication Guide and Prescribing Information, but

---

<sup>17</sup> FDA Approval Letter for NDA 123051/S-011 (Rybelsus) available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/applletter/2022/213051Orig1s011ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2022/213051Orig1s011ltr.pdf) (last visited on 9/20/23).

<sup>18</sup> *Novo Nordisk announces FDA approval of label update for Rybelsus® (semaglutide) allowing use as a first-line option for adults with type 2 diabetes*, Cision PR Newswire (Jan. 12, 2023), available at <https://www.prnewswire.com/news-releases/novo-nordisk-announces-fda-approval-of-label-update-for-rybelsus-semaglutide-allowing-use-as-a-first-line-option-for-adults-with-type-2-diabetes-301720965.html> (last visited on 9/20/23).

gastroparesis was not identified as a side effect or risk.<sup>19</sup>

### C. Novo Nordisk's Marketing and Promotion of Ozempic

40. On December 5, 2017, Novo Nordisk announced the FDA's approval of Ozempic (semaglutide) 0.5 mg or 1 mg injection in a press release stating that: "Novo Nordisk expects to launch OZEMPIC® in the U.S. in Q1 2018, with a goal of ensuring broad insurance coverage and patient access to the product. OZEMPIC® will be priced at parity to current market-leading weekly GLP-1RAs and will be offered with a savings card program to reduce co-pays for eligible commercially-insured patients. Additionally, as part of the access strategy, Novo Nordisk is working with appropriate health insurance providers to establish innovative contracting solutions."<sup>20</sup>

41. On February 5, 2018, Novo Nordisk announced that it had started selling Ozempic in the United States and touted the medication as a "new treatment option[]" that "addresses the concerns and needs of people with diabetes[.]" Novo Nordisk offered an "Instant Savings Card to reduce co-pays to as low as \$25 per prescription fill for up to two years."<sup>21</sup>

42. Novo Nordisk promoted the safety and sale of Ozempic in the United States on its websites, in press releases, through in-person presentations, through the drug's label, in print materials, on social media, and through other public outlets.

43. On July 30, 2018, Novo Nordisk launched its first television ad for Ozempic, to the

---

<sup>19</sup> Novo Nordisk, *Novo Nordisk announces FDA approval of label update for Rybelsus® (semaglutide) allowing use as a first-line option for adults with type 2 diabetes* (Jan. 12, 2023), available at <https://www.novonordisk-us.com/media/news-archive/news-details.html?id=154651> (last visited on 9/21/23).

<sup>20</sup> *Novo Nordisk Receives FDA Approval of OZEMPIC® (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes*, Cision PR Newswire (December 05, 2017), available at <https://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-of-ozempic-semaglutide-injection-for-the-treatment-of-adults-with-type-2-diabetes-300567052.html> (visited on 9/26/23).

<sup>21</sup> *Novo Nordisk Launches Ozempic® and Fiasp®, Expanding Treatment Options for Adults with Diabetes*, Cision PR Newswire (February 05, 2018), available at <https://www.prnewswire.com/news-releases/novo-nordisk-launches-ozempic-and-fiasp-expanding-treatment-options-for-adults-with-diabetes-300592808.html> (visited on 9/26/23).

tune of the 1970s hit pop song “Magic” by Pilot, wherein Novo Nordisk advertised that “adults lost on average up to 12 pounds” when taking Ozempic, even though it is not indicated for weight loss.<sup>22</sup>

44. On March 28, 2022, Novo Nordisk announced the FDA’s approval of sNDA 209637/S-009 for a higher 2 mg dose of Ozempic (semaglutide) injection. In the press release, Novo Nordisk represented Ozempic as having “proven safety” and advertised that “plus it can help many patients lose some weight.”<sup>23</sup>

45. Since 2018, Novo Nordisk has spent more than \$884,000,000 on television ads in the United States to promote its semaglutide drugs (Ozempic, Wegovy and Rybelsus) with the majority of the spending allocated specifically to advertising Ozempic.<sup>24</sup>

46. In 2022, Novo Nordisk spent \$180.2 million on Ozempic ads, including an estimated \$157 million on national television ads for Ozempic, making Ozempic the sixth most advertised drug that year. As a result of its GLP-1RA treatments, including Ozempic, Novo Nordisk forecasts sales growth of 13% to 19% for 2023.<sup>25</sup>

47. On July 6, 2023, it was reported that Novo Nordisk had spent \$11 million in 2022 on food and travel for doctors “as part of its push to promote Ozempic and other weight loss-inducing diabetes drugs.”<sup>26</sup> The spending bought more than 457,000 meals for almost 12,000

---

<sup>22</sup> *Ozempic TV Spot, ‘Oh!’*, iSpot.tv (July 30, 2018), available at <https://www.ispot.tv/ad/d6Xz/ozempic-oh> (visited on 9/26/23).

<sup>23</sup> *Novo Nordisk receives FDA approval of higher-dose Ozempic® 2 mg providing increased glycemic control for adults with type 2 diabetes*, Cision PR Newswire (March 28, 2022), available at <https://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-of-higher-dose-ozempic-2-mg-providing-increased-glycemic-control-for-adults-with-type-2-diabetes-301512209.html> (visited on 10/16/23).

<sup>24</sup> Ritzau, *Novo Nordisk runs TV ads in US for multimillion-dollar sum*, MedWatch (April 26, 2023), available at [https://medwatch.com/News/Pharma\\_Biotech/article15680727.ece](https://medwatch.com/News/Pharma_Biotech/article15680727.ece) (visited on 9/26/23).

<sup>25</sup> Adams B, Fierce Pharma, *The top 10 pharma drug ad spenders for 2022*, <https://www.fiercepharma.com/special-reports/top-10-pharma-drug-brand-ad-spenders-2022> (visited on 9/26/23).

<sup>26</sup> Nicolas Florko, *Novo Nordisk bought prescribers over 450,000 meals and snacks to promote drugs like Ozempic*, National Center for Health Research (July 5, 2023), available at <https://www.center4research.org/novo-nordisk-gave-doctors-450000-meals-ozempic/> (visited on 9/26/23).

doctors while also flying doctors to places like London, Paris, Orlando, and Honolulu.<sup>27</sup>

48. In an article published on July 21, 2023, the President and CEO of the Alliance of Community Health Plans described Novo Nordisk's spending on meals for doctors as "outrageous" and suggested that the millions Novo Nordisk spent marketing its drugs to prescribers would be better used furthering research about potential side effects and long-term effectiveness. The author cited research published in the spring of 2023 showing an increased risk of intestinal obstruction as a result of using GLP-1RA drugs.<sup>28</sup>

49. As a result of Novo Nordisk's advertising and promotion efforts, Ozempic has been widely used throughout the United States. The number of prescriptions filled reached an all-time high of 373,000 in one week in February of 2023, with more than half of those being new prescriptions.<sup>29</sup> In June 2023, it was reported that new prescriptions for Ozempic had surged by 140 percent from the prior year.<sup>30</sup>

50. On TikTok, the hashtag #Ozempic had 273 million views as of November 22, 2022,<sup>31</sup> and currently has over 1.3 billion views.<sup>32</sup>

---

<sup>27</sup> Nicolas Florko, *Novo Nordisk bought prescribers over 450,000 meals and snacks to promote drugs like Ozempic*, National Center for Health Research (July 5, 2023), available at <https://www.center4research.org/novo-nordisk-gave-doctors-450000-meals-ozempic/> (visited on 9/26/23).

<sup>28</sup> Erin Prater, *Ozempic manufacturer Novo Nordisk spent \$11 million last year 'winning and dining' doctors. Experts slam the move as a breach of doctor-patient trust*, Fortune Well (July 21, 2023), available at <https://fortune.com/well/2023/07/21/ozempic-novo-nordisk-meals-travel-prescribing-doctors/> (visited on 9/26/23); see also Erin Prater, *Weight-loss drugs like Ozempic and Wegovy may put certain people at risk of serious complications, researchers warn*, Fortune Well (March 7, 2023), available at <https://fortune.com/well/2023/03/07/ozempic-wegovy-elevated-risk-intestinal-obstruction-later-type-2-diabetes-weight-loss-drug/> (visited on 10/18/23).

<sup>29</sup> Choi A, Vu H, *Ozempic prescriptions can be easy to get online. Its popularity for weight loss is hurting those who need it most*, CNN (March 17, 2023), available at <https://www.cnn.com/2023/03/17/health/ozempic-shortage-tiktok-telehealth/> (visited on 9/26/23).

<sup>30</sup> Gilbert D, *Insurers clamping down on doctors who prescribe Ozempic for weight loss*, The Washington Post (June 12, 2023), available at <https://www.washingtonpost.com/business/2023/06/11/weight-loss-ozempic-wegovy-insurance/> (visited on 9/26/23).

<sup>31</sup> Blum D, *What is Ozempic and Why Is It Getting So Much Attention?*, The New York Times (published Nov. 22, 2022, updated July 24, 2023), available at <https://www.nytimes.com/2022/11/22/well/ozempic-diabetes-weight-loss.html> (visited on 9/26/23).

<sup>32</sup> <https://www.tiktok.com/tag/ozempic> (visited on 11/14/23).

51. On June 15, 2023, NBC News published a report about the “thousands of weight-loss ads on social media for the drugs Ozempic and Wegovy.” While many of those ads were found to be from online pharmacies, medical spas, and diet clinics, as of June of 2023, Novo Nordisk was still running online social-media ads for its semaglutide products, despite claiming in May that it would stop running ads due to a shortage of the drug.<sup>33</sup>

52. On July 10, 2023, a global media company declared Ozempic as “2023’s buzziest drug” and one of the “Hottest Brands, disrupting U.S. culture and industry.”<sup>34</sup>

53. At all relevant times, Novo Nordisk was in the business of and did design, research, manufacture, test, advertise, promote, market, sell, and/or distribute Ozempic.

**D. Novo Nordisk’s Marketing and Promotion of Rybelsus**

54. On September 20, 2019, the Novo Nordisk Defendants announced the FDA’s approval of Rybelsus (semaglutide) tablets 7 mg or 14 mg in a press release stating that: “Rybelsus ... will be available in the U.S. beginning in Q4 2019.... Initial supply of Rybelsus will come from manufacturing facilities in Denmark; however, future supply for Rybelsus will come from ... a new manufacturing facility in Clayton, NC to prepare for the future demand of Rybelsus.” The Novo Nordisk Defendants further stated that they were “working with health insurance providers with a goal of ensuring broad insurance coverage and patient access to the product. A savings card program will be available at the time of launch for eligible commercially-insured patients to keep out of pocket costs down to as little as \$10 a month.” The Novo Nordisk Defendants acknowledged that the most common side effects associated with the use of Rybelsus included nausea, stomach

---

<sup>33</sup> Ingram D, *More than 4,000 ads for Ozempic-style drugs found running on Instagram and Facebook*, NBC News (June 15, 2023), available at <https://www.nbcnews.com/tech/internet/ozempic-weight-loss-drug-ads-instagram-wegovy-semaglutide-rcna88602> (visited on 9/26/23).

<sup>34</sup> Bain P, *Ozempic was 2023’s Buzziest Drug*, AdAge (July 10, 2023), available at <https://adage.com/article/special-report-hottest-brands/ozempic-hottest-brands-most-popular-marketing-2023/2500571> (visited on 9/26/23).

(abdominal) pain, diarrhea, decreased appetite, vomiting, and constipation. While the Novo Nordisk Defendants listed possible thyroid tumors (including cancer), inflammation of the pancreas, changes in vision, low blood sugar, kidney problems, and serious allergic reactions as “serious side effects”, they failed to list gastroparesis.<sup>35</sup>

55. On January 16, 2020, the Novo Nordisk Defendants announced FDA approval of Rybelsus (semaglutide) tablets 7 mg and 14 mg prescribing information based on clinical data from the PIONEER 6 cardiovascular outcomes. In their announcement, the Novo Nordisk Defendants acknowledged that the most common side effects of Rybelsus are “nausea, stomach (abdominal) pain, diarrhea, decreased appetite, vomiting, and constipation.” While the Novo Nordisk Defendants listed possible thyroid tumors (including cancer), inflammation of the pancreas, changes in vision, low blood sugar, kidney problems (kidney failure), and serious allergic reactions as “serious side effects”, they failed to list severe gastrointestinal events, including gastroparesis.<sup>36</sup>

56. On January 12, 2023, the Novo Nordisk Defendants announced FDA approval of a label update for Rybelsus (semaglutide) allowing its use as a first-line option for adult with type 2 diabetes. The update removed the previous limitation that Rybelsus could not be used as an initial therapy option for treating patients with type 2 diabetes. The announcement reiterated that the Novo Nordisk Defendants “work[] with health insurance providers to ensure broad insurance coverage and patient access to Rybelsus. Eligible, commercially insured patients may pay as little

---

<sup>35</sup> *FDA approves Rybelsus (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes*, Cision PR Newswire (September 20, 2019), available at <https://www.prnewswire.com/news-releases/fda-approves-rybelsus-semaglutide-the-first-glp-1-analog-treatment-available-in-a-pill-for-adults-with-type-2-diabetes-300922438.html> (last visited on 9/20/23).

<sup>36</sup> *FDA approves Ozempic for cardiovascular risk reduction in adults with type 2 diabetes and known heart disease, updates Rybelsus label*, Cision PR Newswire (January 16, 2020), available at <https://www.prnewswire.com/news-releases/fda-approves-ozempic-for-cardiovascular-risk-reduction-in-adults-with-type-2-diabetes-and-known-heart-disease-updates-rybelsus-label-300988672.html> (last visited on 9/20/23).

as \$10 for a one- to three-month prescription of this medicine.” The Novo Nordisk Defendants acknowledged that the most common side effects of Rybelsus are “nausea, stomach (abdominal) pain, diarrhea, decreased appetite, vomiting, and constipation.” While the Novo Nordisk Defendants listed possible thyroid tumors (including cancer), inflammation of the pancreas, changes in vision, low blood sugar, kidney problems (kidney failure), serious allergic reactions, and gallbladder problems as “serious side effects”, they did not list gastroparesis as a side effect or risk, nor did they otherwise mention it.<sup>37</sup>

57. The Novo Nordisk Defendants promoted the safety and sale of Rybelsus in the United States on its websites, in press releases, through in-person presentations, through the drug’s label, in print materials, on social media, and through other public outlets.

58. On September 22, 2020, the Novo Nordisk Defendants launched their first television ad for Rybelsus featuring an upbeat cover version of “You Are My Sunshine” by Simon Ravenhall. In the ad, the Novo Nordisk Defendants advertised that “people taking Rybelsus lost up to 8 pounds”, even though it is not a weight loss drug.<sup>38</sup> Also, the Novo Nordisk Defendants identified only one “serious side effect” of taking Rybelsus in the ad, pancreatitis.

59. From 2018 until present, the Novo Nordisk Defendants have spent \$884,000,000 on running television ads in the United States to promote their semaglutide drugs (Ozempic, Wegovy and Rybelsus).<sup>39</sup>

60. In 2021, the Novo Nordisk Defendants spent \$307.6 million on Rybelsus ads,

---

<sup>37</sup> *Novo Nordisk announces FDA approval of label update for Rybelsus (semaglutide) allowing use as first-line option for adults with type 2 diabetes*, Cision PR Newswire (January 23, 2023), available at <https://www.prnewswire.com/news-releases/novo-nordisk-announces-fda-approval-of-label-update-for-rybelsus-semaglutide-allowing-use-as-a-first-line-option-for-adults-with-type-2-diabetes-301720965.html> (last visited on 9/20/23).

<sup>38</sup> *Ozempic TV Spot, “Wake Up”*, iSpot.tv (September 2020), available at <https://www.ispot.tv/ad/nvgx/rybelsus-wake-up> (last visited on 9/20/23).

<sup>39</sup> Ritzau, *Novo Nordisk runs TV ads in US for multimillion-dollar sum*, MedWatch (April 26, 2023), available at [https://medwatch.com/News/Pharma\\_\\_\\_Biotech/article15680727.ece](https://medwatch.com/News/Pharma___Biotech/article15680727.ece) (last visited on 9/20/23).

making it the No. 2 top spender that year.<sup>40</sup> In 2022, the Novo Nordisk Defendants spent \$167.2 million on Rybelsus advertisements, making it the No. 7 top spender last year.<sup>41</sup> In 2022, the Novo Nordisk Defendants spent an estimated \$123.9 million on Rybelsus television ads alone.<sup>42</sup> More than 60% of the Novo Nordisk Defendants' television advertisement budget was for a single ad "Down With Rybelsus" that sought to make the case for switching from other GLP-1RA's to Rybelsus.<sup>43</sup> The commercial featured an actor playing a physician with a voice-over stating that Rybelsus lowered A1C better than "a leading branded pill", referring to Merck & Co.'s diabetes drug, Januvia.<sup>44</sup> The television ad identified only one "serious side effect" of taking Rybelsus, pancreatitis.<sup>45</sup> As a result of its GLP-1RA treatments, including Rybelsus, the Novo Nordisk Defendants forecast sales growth of 13% to 19% for 2023.<sup>46</sup>

61. On July 5, 2023, it was reported that the Novo Nordisk Defendants had spent \$11,000,000 on food and travel for doctors as part of their efforts to promote their GLP-1 medications, including Rybelsus. In 2022 alone, the Novo Nordisk Defendants bought more than 457,000 meals to educate doctors and other prescribers about its GLP-1, with nearly 12,000 doctors receiving more than 50 meals and snacks from the Novo Nordisk Defendants. In 2022, the Novo Nordisk Defendants also spent \$2 million flying doctors to London, Paris, Orlando, and Honolulu related to its GLP-1s.<sup>47</sup>

---

<sup>40</sup> Adams B, Fierce Pharma, *The top 10 pharma drug ad spenders for 2022*, <https://www.fiercepharma.com/special-reports/top-10-pharma-drug-brand-ad-spenders-2022> (last visited on 9/20/23).

<sup>41</sup> Adams B, Fierce Pharma, *The top 10 pharma drug ad spenders for 2022*, <https://www.fiercepharma.com/special-reports/top-10-pharma-drug-brand-ad-spenders-2022> (last visited on 9/20/23).

<sup>42</sup> Adams B, Fierce Pharma, *The top 10 pharma drug ad spenders for 2022*, <https://www.fiercepharma.com/special-reports/top-10-pharma-drug-brand-ad-spenders-2022> (last visited on 9/20/23).

<sup>43</sup> *Down With RYBELSUS*, <https://www.ispot.tv/ad/btuw/rybelsus-down-with-rybelsus> (last visited on 9/20/23).

<sup>44</sup> *Down With RYBELSUS*, <https://www.ispot.tv/ad/btuw/rybelsus-down-with-rybelsus> (last visited on 9/20/23).

<sup>45</sup> *Down With RYBELSUS*, <https://www.ispot.tv/ad/btuw/rybelsus-down-with-rybelsus> (last visited on 9/20/23).

<sup>46</sup> Adams B, Fierce Pharma, *The top 10 pharma drug ad spenders for 2022*, <https://www.fiercepharma.com/special-reports/top-10-pharma-drug-brand-ad-spenders-2022> (last visited on 9/20/23).

<sup>47</sup> Florko, N, *Novo Nordisk bought prescribers over 450,000 meals and snacks to promote drugs like Ozempic*, National Center for Health Research (July 5, 2023), available at <https://www.center4research.org/novo-nordisk-gave-doctors-450000-meals-ozempic> (last visited on 9/20/23).

62. On July 21, 2023, it was reported that Novo Nordisk had purchased more than 457,000 meals—at a total price of more than \$9 million—to educate prescribers about its GLP-1s. The president and CEO of the Alliance of Community, who was interviewed for the article, described the expenditures as “outrageous” and suggested that the millions Novo Nordisk spent marketing its drugs to prescribers would be better used furthering research about their potential side effects and long-term effectiveness. The author pointed out that research published in spring 2023 “suggested that GLP-1s could put patients at an elevated risk of a potentially fatal gastrointestinal condition that requires surgery.”<sup>48</sup>

63. As a result of the Novo Nordisk Defendants’ advertising and promotion efforts, Rybelsus has been widely used throughout the United States. In its inaugural year alone, Rybelsus “defied full-year sales expectations in 2020” topping \$350 million. Over 80% of these Rybelsus prescriptions were from patients new to the GLP-1RA class, not significantly dipping into the Novo Nordisk Defendants’ already strong market position with Ozempic.<sup>49</sup>

64. On TikTok, there are currently over 54.5M views on #rybelsus-review, 46 million views on #rybelsus, and 44.1M views on #rybelsus-experience.<sup>50</sup>

65. On June 15, 2023, NBC News published a report about the thousands of weight loss advertisements on social media for Defendants’ drugs, including Rybelsus. While many of those ads were found to be from online pharmacies, medical spas, and diet clinics, as of June of 2023 the Novo Nordisk Defendants were still running online social-media ads for their semaglutide

---

<sup>48</sup> Erin Prater, *Ozempic manufacturer Novo Nordisk spent \$11 million last year ‘winning and dining’ doctors. Experts slam the move as a breach of doctor-patient trust*, Fortune Well (July 21, 2023), available at <https://fortune.com/well/2023/07/21/ozempic-novo-nordisk-meals-travel-prescribing-doctors/> (last visited on 9/19/23).

<sup>49</sup> *Novo Nordisk’s Rybelsus launch defied 2020 full-year sales expectations, despite the economic impacts of the Covid-19 pandemic*, Pharmaceutical Technology (February 12, 2021), available at <https://www.pharmaceutical-technology.com/comment/novo-nordisk-rybelsus-launch-sales> (last visited on 9/20/23).

<sup>50</sup> <https://www.tiktok.com/discover/rybelsus-review>; <https://www.tiktok.com/discover/rybelsus>; <https://www.tiktok.com/discover/rybelsus-experience> (last visited on 9/22/23).

products, despite claiming in May that they would stop running ads due to a shortage of the drug.<sup>51</sup>

66. On June 25, 2023, NBC News reported that the Novo Nordisk Defendants anticipate filing for FDA approval for Rybelsus for weight loss in people who are obese or overweight, and do not have type 2 diabetes. ADA chief scientist, Dr. Robert Gabbay, called the development “a game changer.”<sup>52</sup>

67. At all relevant times, Novo Nordisk was in the business of and did design, research, manufacture, test, advertise, promote, market, sell, and/or distribute Rybelsus.

**E. The Medical Literature and Clinical Trials Gave Defendants Notice of Gastroparesis Being Causally Associated with GLP-1RAs.**

68. As previously noted, Ozempic (semaglutide) and Rybelsus (semaglutide) belong to a class of drugs called GLP-1 receptor agonists (“GLP-1RAs”).

69. Medications within the GLP-1RA class of drugs mimic the activities of physiologic GLP-1, which is a gut hormone that activates the GLP-1 receptor in the pancreas to stimulate the release of insulin and suppress glucagon.<sup>53</sup>

70. Because the risk of gastroparesis is common to the entire class of drugs, any published literature regarding the association between gastroparesis and *any* GLP-1RA (such as tirzepatide, exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide, and semaglutide) should have put Defendants on notice of the need to warn patients and prescribing physicians of the risk of gastroparesis associated with these drugs.

71. In addition to pancreatic effects, the published medical literature shows that GLP-

---

<sup>51</sup> Ingram D, *More than 4,000 ads for Ozempic-style drugs found running on Instagram and Facebook*, NBC News (June 15, 2023), available at <https://www.nbcnews.com/tech/internet/ozempic-weight-loss-drug-ads-instagram-wegovy-semaglutide-rcna88602> (last visited on 9/19/23).

<sup>52</sup> Lovelace, B, *Effective pills for weight loss, including an oral version of Ozempic, are on the horizon*, NBC News (June 25, 2023), available at <https://www.nbcnews.com/health/health-news/effective-pills-weight-loss-oral-version-ozempic-are-horizon-rcna90981> (last visited on 9/20/23).

<sup>53</sup> Hinnen D, *Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes*, 30(3) *Diabetes Spectr.*, 202–210 (August 2017), available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556578/> (visited on 9/26/23).

1 slows gastric emptying. As early as 2010, a study published in The Journal of Clinical Endocrinology & Metabolism indicated this effect.<sup>54</sup>

72. Defendants knew or should have known of this risk of gastroparesis from the clinical trials, medical literature, and case reports.

73. A 2016 trial funded by Novo Nordisk measuring semaglutide and cardiovascular outcomes in patients with type 2 diabetes found more gastrointestinal disorders in the semaglutide group than in the placebo group, including a severe adverse event report of impaired gastric emptying with semaglutide 0.5 mg together with other serious gastrointestinal adverse events such as abdominal pain (upper and lower), intestinal obstruction, change of bowel habits, vomiting, and diarrhea.<sup>55</sup>

74. Two subjects in a semaglutide trial pool by Novo Nordisk reported moderate adverse events of impaired gastric emptying and both subjects permanently discontinued treatment due to the adverse events. Three subjects also reported mild adverse events of impaired gastric emptying in the semaglutide run-in period of trial 4376. The cardiovascular outcomes trials included two cases of gastroparesis with the first subject being diagnosed with severe gastroparesis after one month in the trial and second subject being diagnosed with gastroparesis after approximately two months in the trial.

75. A study published in 2017 evaluated the effect of GLP-1RAs on gastrointestinal

---

<sup>54</sup> Deane AM et al., *Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia*, 95(1) J Clinical Endo Metabolism, 225-221 (January 1, 2010), available at <https://academic.oup.com/jcem/article/95/1/215/2835243> (visited on 9/26/23); American Society of Anesthesiologists, *Patients Taking Popular Medications for Diabetes and Weight Loss Should Stop Before Elective Surgery, ASA Suggests* (June 29, 2023), available at <https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/patients-taking-popular-medications-for-diabetes-and-weight-loss-should-stop-before-elective-surgery> (visited on 9/26/23).

<sup>55</sup> Marso, SP, et al., *Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes*, N. Eng. J. Med. 375:1834-1844 (November 2016), available at <https://www.nejm.org/doi/10.1056/NEJMoa1607141> (visited on 10/19/23).

tract motility and residue rates and explained that “GLP-1 suppresses gastric emptying by inhibiting peristalsis of the stomach while increasing tonic contraction of the pyloric region.” The study authors concluded that the GLP-1RA drug liraglutide “exhibited gastric-emptying delaying effects” and “the drug also inhibited duodenal and small bowel movements at the same time.”<sup>56</sup>

76. Another study in 2017 reviewed the survey results from 10,987 patients and 851 physicians and found that “GI-related issues were the top two patient-reported reasons for GLP-1RA discontinuation in the past 6 months, with ‘Made me feel sick’ as the most frequently reported reason (64.4%), followed by ‘Made me throw up’ (45.4%).”<sup>57</sup> As explained above, these are symptoms of gastroparesis.

77. A 2019 study of the GLP-1RA drug dulaglutide identified adverse events for impaired gastric emptying and diabetic gastroparesis.

78. In August of 2020, medical literature advised that some “patients do not know they have diabetic gastroparesis until they are put on a glucagon-like peptide 1 (GLP-1) receptor agonist such as ... semaglutide ... to manage their blood glucose.” The article went on to explain that “[t]his class of drugs can exacerbate the symptoms of diabetic gastroparesis. ... Thus, GLP-1 receptor agonist therapy is not recommended for people who experience symptoms of gastroparesis.”<sup>58</sup>

79. In a September 2020 article funded and reviewed by Novo Nordisk, scientists affiliated with Novo Nordisk reported on two global clinical trials that evaluated the effect of semaglutide in patients with cardiovascular events and diabetes. More patients permanently

---

<sup>56</sup> Nakatani Y et al., *Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy*, 43(5) *Diabetes & Metabolism*, 430-37 (October 2017), available at <https://www.sciencedirect.com/science/article/pii/S1262363617301076> (visited on 9/26/23).

<sup>57</sup> Sikirica M et al., *Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes*, 10 *Diabetes Metab. Syndr. Obes.*, 403-412 (September 2017), available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630073/>

<sup>58</sup> Young CF, Moussa M, Shubrook JH, *Diabetic Gastroparesis: A Review*, *Diabetes Spectr.* (2020), Aug; 33(3): 290–297, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428659/> (visited on 9/26/23).

discontinued taking oral semaglutide (11.6%) than placebo (6.5%) due to adverse events. The most common adverse events associated with semaglutide were nausea (2.9% with semaglutide versus 0.5% with placebo), vomiting (1.5% with semaglutide versus 0.3% with placebo), and diarrhea (1.4% with semaglutide versus 0.4% with placebo). Injectable semaglutide had a discontinuation rate of 11.5-14.5% (versus 5.7-7.6% with placebo) over a two-year period. The authors acknowledged the potential for severe gastrointestinal events, warning that “[f]or patients reporting severe adverse gastrointestinal reactions, it is advised to monitor renal function when initiating or escalating doses of oral semaglutide.” For patients with other comorbidities, the study warned that “patients should be made aware of the occurrence of gastrointestinal adverse events with GLP-IRAs.” The study further identified as one “key clinical take-home point” that “patients should be made aware of the occurrence of gastrointestinal adverse events with GLP-IRAs.”<sup>59</sup>

80. A July 2021 article funded and reviewed by Novo Nordisk considered 23 randomized control trials conducted across the United States, Japan, and China and concluded that “gastrointestinal disturbances” were “well-known” side effects associated with semaglutide use. When compared with placebos, the subcutaneous (injection) form of the drug induced nausea in up to 20% of patients (versus up to 8% on the placebo group), vomiting in up to 11.5% of patients (versus up to 3% in the placebo group) and diarrhea in up to 11.3% of patients (versus up to 6% in the placebo group). Overall, the percentage of patients experiencing adverse events that led to trial product discontinuation was greatest for gastrointestinal related adverse events, with some trials experiencing 100% discontinuation due to gastrointestinal related adverse events. The mean value of gastrointestinal related adverse events that led to discontinuation averaged 57.75%. The study

---

<sup>59</sup> Mosenzon O, Miller EM, & Warren ML, *Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients*, Postgraduate Medicine (2020), 132:sup2, 37-47, available at <https://doi.org/10.1080/00325481.2020.1800286> (visited on 9/26/23).

acknowledges that while nausea and vomiting are unwanted side effects, “they may be partly responsible for aspects of the drug’s efficacy[.]”<sup>60</sup>

81. An October 2021 article in the Journal of Investigative Medicine (“JIM”) concluded that because gastroparesis can be associated with several medications, “[i]t is crucial to identify the causative drugs as discontinuation of the drug can result in resolution of the symptoms[.]” In diabetics, making this determination can be particularly “tricky” because both diabetes and GLP-1RAs can cause delayed gastric emptying. As such, “the timeline of drug initiation and symptom onset becomes of the upmost importance.” The authors reviewed two case reports (discussed below) and concluded that history taking and making an accurate diagnosis of diabetic gastroparesis versus medication-induced gastroparesis is critical.<sup>61</sup>

82. Case Report #1 in JIM involved a 52-year-old female with long-standing (10 years) well-controlled, type 2 diabetes who had been taking weekly semaglutide injections approximately one month prior to the onset of gastroparesis symptoms. The patient was referred with a 7-month history of post-prandial epigastric pain, accompanied by fullness, bloating, and nausea. A gastric emptying study showed a 24% retention of isotope in the patient’s stomach at four hours, indicative of delayed gastric emptying. The patient discontinued semaglutide and her symptoms resolved after six weeks. The case report authors concluded that “thorough history taking revealed the cause [of gastroparesis] to be medication induced.”<sup>62</sup>

83. Case Report #2 in JIM involved a 57-year-old female with a long-standing (16

---

<sup>60</sup> Smits MM & Van Raalte DH (2021), *Safety of Semaglutide*, Front. Endocrinol., 07 July 2021, doi: 10.3389/fendo.2021.645563, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294388/> (visited on 9/26/23).

<sup>61</sup> Kalas MA, Galura GM, McCallum RW, *Medication-Induced Gastroparesis: A Case Report*, J Investig Med High Impact Case Rep. 2021 Jan-Dec; 9: 23247096211051919, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529310/> (visited on 9/26/23).

<sup>62</sup> Kalas MA, Galura GM, McCallum RW, *Medication-Induced Gastroparesis: A Case Report*, J Investig Med High Impact Case Rep. 2021 Jan-Dec; 9: 23247096211051919, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529310/> (visited on 9/26/23).

years) type 2 diabetes who had been taking weekly dulaglutide injections (another GLP-1RA) for 15 months and suffering from abdominal bloating, nausea, and vomiting for 12 of those months. A gastric emptying study showed 35% retention of isotope in the patient's stomach at four hours, indicating delayed gastric emptying. After discontinuing dulaglutide, the patient experienced a gradual resolution of symptoms over a four-week period.<sup>63</sup>

84. A June 2022 study reported GLP-1RA Mounjaro (tirzepatide) adverse events of vomiting, nausea, and "severe or serious gastrointestinal events."<sup>64</sup>

85. An October 2022 study analyzed 5,442 GLP-1RA adverse gastrointestinal events. 32% were serious, including 40 deaths, 53 life-threatening conditions, and 772 hospitalizations. The primary events were nausea and vomiting. There were also adverse events for impaired gastric emptying.<sup>65</sup>

86. A January 2023 meta-analysis of GLP-1RA (Mounjaro) adverse events reported high rates of nausea and vomiting.<sup>66</sup>

87. In February 2023, a longitudinal study of GLP-1RA (dulaglutide) reported adverse events for nausea and vomiting, and one adverse event of impaired gastric emptying.<sup>67</sup>

88. On March 28, 2023, a case study concluded that impaired gastric emptying is "a significant safety concern, especially since it is consistent with the known mechanism of action of

---

<sup>63</sup> Kalas MA, Galura GM, McCallum RW, *Medication-Induced Gastroparesis: A Case Report*, J Investig Med High Impact Case Rep. 2021 Jan-Dec; 9: 23247096211051919, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529310/> (visited on 9/26/23).

<sup>64</sup> Jastreboff, *Tirzepatide Once Weekly for the Treatment of Obesity*, N Engl J Med, at 214 (June 4, 2022) (<https://doi.org/10.1056/nejmoa2206038>).

<sup>65</sup> Shu, *Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system*, Front. Public Health (Oct. 20, 2022). (<https://doi.org/10.3389%2Ffpubh.2022.996179>).

<sup>66</sup> Mirsha, *Adverse Events Related to Tirzepatide*, J. of Endocrine Society (Jan. 26, 2023) (<https://doi.org/10.1210%2Fjendso%2Fbvad016>).

<sup>67</sup> Chin, *Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real-world clinical practice: 36 month postmarketing observational study*, J Diabetes Investig (Feb. 2023) (<https://doi.org/10.1111%2Fjdi.13932>).

the drug.”<sup>68</sup>

89. On June 29, 2023, the American Society of Anesthesiologists (“ASA”) warned that patients taking semaglutide and other GLP-1RAs should stop the medication at least a week before elective surgery because these medications “delay gastric (stomach) emptying” and “the delay in stomach emptying could be associated with an increased risk of regurgitation and aspiration of food into the airways and lungs during general anesthesia and deep sedation.” The ASA also warned that the risk is higher where patients on these medications have experienced nausea and vomiting.<sup>69</sup>

90. News sources have identified the potential for serious side effects in users of Ozempic, including gastroparesis, leading to hospitalization.<sup>70</sup> For example, NBC News reported in January 2023 that some Ozempic users were discontinuing use because their symptoms were unbearable, and one user said that five weeks into taking the medication she found herself unable to move off the bathroom floor because she had “vomited so much that [she] didn’t have the energy to get up.”<sup>71</sup> CNN reported in July that one Ozempic user diagnosed with gastroparesis vomits so

---

<sup>68</sup> Klein, Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report, *Can J. Anesth* (Mar. 28, 2023) (<https://doi.org/10.1007/s12630-023-02440-3>).

<sup>69</sup> American Society of Anesthesiologists, *Patients Taking Popular Medications for Diabetes and Weight Loss Should Stop Before Elective Surgery, ASA Suggests* (June 29, 2023), available at <https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/patients-taking-popular-medications-for-diabetes-and-weight-loss-should-stop-before-elective-surgery> (visited on 9/26/23).

<sup>70</sup> Penny Min, *Ozempic May Cause Potential Hospitalizations*, *healthnews* (June 26, 2023), available at <https://healthnews.com/news/ozempic-may-cause-potential-hospitalizations/> (visited on 9/26/23); Elizabeth Laura Nelson, *These Are the 5 Most Common Ozempic Side Effects, According to Doctors*, *Best Life* (April 3, 2023), available at <https://bestlifeonline.com/ozempic-side-effects-news/> (visited on 9/26/23); Cara Shultz, *Ozempic and Wegovy May Cause Stomach Paralysis in Some Patients*, *People* (July 26, 2023), available at <https://people.com/ozempic-wegovy-weight-loss-stomach-paralysis-7565833> (visited on 9/26/23); CBS News Philadelphia, *Popular weight loss drugs Ozempic and Wegovy may cause stomach paralysis, doctors warn* (July 23, 2023), available at <https://www.cbsnews.com/philadelphia/news/weight-loss-drugs-wegovy-ozempic-stomach-paralysis/> (visited on 9/26/23).

<sup>71</sup> Bendix A, Lovelace B Jr., *What it’s like to take the blockbuster drugs Ozempic and Wegovy, from severe side effects to losing 50 pounds*, *NBC News* (Jan. 29, 2023), available at <https://www.nbcnews.com/health/health-news/ozempic-wegovy-diabetes-weight-loss-side-effects-rcna66493> (visited on 9/26/23).

frequently that she had to take a leave of absence from her teaching job.<sup>72</sup>

91. A July 25, 2023, article in Rolling Stone magazine—“*Ozempic Users Report Stomach Paralysis from Weight Loss Drug: ‘So Much Hell’*”—highlighted three patients who have suffered severe gastrointestinal related events, including gastroparesis, as a result of their use of GLP-1RAs. Patient 1 (female, age 37) reported incidents of vomiting multiple times per day and being unable to eat. The patient’s physician diagnosed her with severe gastroparesis and concluded that her problems were caused and/or exacerbated by her use of a GLP-1RA medication. Patient 2 (female) used Ozempic for one year and reported incidents of vomiting, including multiple times per day. The patient’s physician diagnosed her with severe gastroparesis related to her Ozempic use. Patient 3 (female, age 42) experienced severe nausea both during and after she discontinued use of a GLP-1RA. In a statement to Rolling Stone, Novo Nordisk acknowledged that “[t]he most common adverse reactions, as with all GLP-1 RAs, are gastrointestinal related.” Novo Nordisk further stated that while “GLP-1 RAs are known to cause a delay in gastric emptying, ... [s]ymptoms of delayed gastric emptying, nausea and vomiting are listed as side effects.” Novo Nordisk did not claim to have warned consumers about gastroparesis, or other severe gastrointestinal issues.<sup>73</sup>

92. On July 25, 2023, CNN Health reported that patients taking Ozempic have been diagnosed “with severe gastroparesis, or stomach paralysis, which their doctors think may have resulted from or been exacerbated by the medication they were taking, Ozempic.” Another patient taking Wegovy (semaglutide) suffered ongoing nausea and vomiting, which was not diagnosed,

---

<sup>72</sup> Brenda Goodman, *They took blockbuster drugs for weight loss and diabetes. Now their stomachs are paralyzed*, CNN (July 25, 2023), available at <https://www.cnn.com/2023/07/25/health/weight-loss-diabetes-drugs-gastroparesis/index.html> (visited on 9/26/23).

<sup>73</sup> CT Jones, *Ozempic Users Report Stomach Paralysis from Weight Loss Drug: ‘So Much Hell’*, Rolling Stone (July 25, 2023), available at <https://www.rollingstone.com/culture/culture-news/ozempic-stomach-paralysis-weight-loss-side-effects-1234794601> (visited on 9/26/23).

but which needed to be managed with Zofran and prescription probiotics.<sup>74</sup>

93. On July 26, 2023, a New York hospital published an article to its online health blog section “What You Need to Know About Gastroparesis” entitled “Delayed Stomach Emptying Can Be Result of Diabetes or New Weight-Loss Medicines.” It was reported that a growing number of gastroparesis cases had been seen in people taking GLP-1RAs. The article noted that the weight-loss drugs can delay or decrease the contraction of muscles that mix and propel contents in the gastrointestinal tract leading to delayed gastric emptying. One concern raised was that patients and doctors often assume the symptoms of gastroparesis are reflux or other gastrointestinal conditions, meaning it may take a long time for someone to be diagnosed correctly.<sup>75</sup>

94. In an October 5, 2023, Research Letter published in the Journal of the American Medical Association (“JAMA”), the authors examined gastrointestinal adverse events associated with GLP-1RAs used for weight loss in clinical setting and reported that use of GLP-1RAs compared with use of bupropion-naltrexone was associated with increased risk of pancreatitis, gastroparesis, and bowel obstruction.<sup>76</sup> The study found that patients prescribed GLP-1RAs were at 4.22 times higher risk of intestinal obstruction and at 3.67 times higher risk of gastroparesis.

95. The medical literature listed above is not a comprehensive list, and several other case reports have indicated that GLP-1RAs can cause gastroparesis and impaired gastric

---

<sup>74</sup> Brenca Goodman, *They took blockbuster drugs for weight loss and diabetes. Now their stomachs are paralyzed*, CNN Health (July 25, 2023), available at <https://www.cnn.com/2023/07/25/health/weight-loss-diabetes-drugs-gastroparesis> (last visited on 9/26/23).

<sup>75</sup> *Delayed Stomach Emptying Can Be Result of Diabetes or New Weight-Loss Medicines*, Montefiore Health Blog article (released July 26, 2023), available at <https://www.montefiorenyack.org/health-blog/what-you-need-know-about-gastroparesis> (last visited on 9/26/2023).

<sup>76</sup> Mohit Sodhi, et al., *Risk of Gastrointestinal Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss*, JAMA (published online October 5, 2023), available at <https://jamanetwork.com/journals/jama/fullarticle/2810542> (last visited 10/19/23).

emptying.<sup>77</sup>

96. Defendants knew or should have known of the causal association between the use of GLP-1RAs and the risk of developing gastroparesis and its sequelae, but they ignored the causal association. Defendants’ actual and constructive knowledge derived from their clinical studies, case reports, medical literature, including the medical literature and case reports referenced above in this Complaint.

97. On information and belief, Defendants not only knew or should have known that their GLP-1RAs cause delayed gastric emptying, resulting in risks of gastroparesis, but they may have sought out the delayed gastric emptying effect due to its association with weight loss. For example, a recent study published in 2023 notes that “it has been previously proposed that long-acting GLP-1RAs could hypothetically contribute to reduced energy intake and weight loss by delaying GE [gastric emptying,]” and the study authors suggested “further exploration of peripheral mechanisms through which s.c. semaglutide, particularly at a dose of 2.4. mg/week, could potentially contribute to reduced food and energy intake.”<sup>78</sup>

#### **F. Defendants Failed to Warn of the Risk of Gastroparesis from Ozempic and Rybelsus**

98. The Prescribing Information for Ozempic (the “Ozempic label”) discloses “Warnings and Precautions” and “Adverse Reactions” but does not adequately warn of the risk of

---

<sup>77</sup> Cure, *Exenatide and Rare Adverse Events*, N. Eng. J. Med. (May 1, 2008) (<https://doi.org/10.1056/nejmc0707137>); Rai, *Liraglutide-induced Acute Gastroparesis*, Cureus (Dec. 28, 2018) (<https://doi.org/10.7759/cureus.3791>); Guo, *A Post Hoc Pooled Analysis of Two Randomized Trials*, Diabetes Ther (2020) (<https://doi.org/10.1007%2Fs13300-020-00869-z>); Almustanyir, *Gastroparesis With the Initiation of Liraglutide: A Case Report*, Cureus (Nov. 28, 2020) (<https://doi.org/10.7759/cureus.11735>); Ishihara, *Suspected Gastroparesis With Concurrent Gastroesophageal Reflux Disease Induced by Low-Dose Liraglutide*, Cureus (Jul. 16, 2022) (<https://doi.org/10.7759/cureus.26916>); Preda, *Gastroparesis with bezoar formation in patients treated with glucagon-like peptide-1 receptor agonists: potential relevance for bariatric and other gastric surgery*, BJS Open (Feb. 2023) (<https://doi.org/10.1093%2Fbjsopen%2Fzrac169>).

<sup>78</sup> Jensterle M et al., *Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity*, 25(4) Diabetes Obes. Metab. 975-984 (April 2023), available at <https://dom-pubs.onlinelibrary.wiley.com/doi/epdf/10.1111/dom.14944> (visited on 9/26/23).

gastroparesis and its sequelae.<sup>79</sup>

99. The Ozempic label lists nausea, vomiting, diarrhea, abdominal pain, and constipation as common adverse reactions reported in Ozempic patients, but it does not include these adverse reactions in its “Warnings and Precautions” section, nor does it warn that these adverse reactions are symptoms of more severe conditions, including gastroparesis. In fact, gastroparesis is not mentioned at all in the label.

100. Instead of properly disclosing gastrointestinal risks, the Ozempic label discloses delayed gastric emptying in the “Drug Interaction” section and notes that Ozempic “may impact absorption of concomitantly administered oral medications.” Similarly, in the “Mechanism of Action” section, the label minimizes gastrointestinal risks by stating that “[t]he mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.” These statements only describe the drug’s mechanism of action and do not disclose gastroparesis as a *risk* of taking Ozempic, nor do they disclose gastroparesis as a chronic condition that can result as a consequence of taking Ozempic.

101. Similarly, Novo Nordisk’s main promotional website for Ozempic (ozempic.com) includes a variety of information about the benefits of Ozempic relating to blood sugar, cardiovascular health, and weight loss, as well as “Important Safety Information” – however, Novo Nordisk does not disclose the risk of gastroparesis within the “Important Safety Information” section of their promotional website.<sup>80</sup>

102. In January 2020, Novo Nordisk removed the “Instructions” portion from Section 17 “Patient Counseling Information” of the Ozempic label, which had instructed prescribers to “[a]dvise patients that the most common side effects of Ozempic are nausea, vomiting, diarrhea,

---

<sup>79</sup> <https://www.novo-pi.com/ozempic.pdf>

<sup>80</sup> See Ozempic.com (visited on 10/16/23).

abdominal pain and constipation.” These instructions were present in the 2017 and 2019 labels.

103. The 2017 and 2019 labels for Ozempic also instructed physicians that “vomiting ... decreases over time in the majority of patients.” As a result, a physician would not only fail to appreciate vomiting as a symptom of gastroparesis but, even worse, would encourage a patient to continue using Ozempic despite symptoms of gastroparesis.

104. In its section on “Females and Males of Reproductive Potential,” the Ozempic label advises female users to discontinue Ozempic at least 2 months before a planned pregnancy due to the long washout period for semaglutide. This demonstrates that Novo Nordisk knew or should have known that symptoms, such as continuous and violent vomiting, can linger long after the drugs are discontinued and shows the need to warn of gastroparesis and its sequelae.

105. From the date Novo Nordisk received FDA approval to market Ozempic until the present time, Novo Nordisk made, distributed, marketed, and/or sold Ozempic without adequate warning to Plaintiff’s prescribing physician(s) and/or Plaintiff that Ozempic was causally associated with and/or could cause gastroparesis and its sequelae.

106. The Prescribing Information for Rybelsus (the “Rybelsus label”) discloses warnings, precautions, and adverse reactions, but it does not disclose the risk of gastroparesis. Instead, it discloses delayed gastric emptying under the “Drug Interactions” heading and notes that Rybelsus “has the potential to impact the absorption of other oral medications.” Further, under the “Mechanism of Action” section, the Prescribing Information states that “[t]he mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.”<sup>81</sup> These statements do not disclose gastroparesis or delayed gastric emptying as *risks* of taking Rybelsus, nor do they disclose gastroparesis as a side effect or condition that can result as

---

<sup>81</sup> Rybelsus prescribing information, available at <http://www.novo-pi.com/rybelsus.pdf> (last visited on 9/20/23).

a consequence of taking Rybelsus.

107. The Rybelsus label lists nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation as common adverse reactions reported in Rybelsus patients but does not include vomiting in its “Warnings and Precautions” section, and it does not indicate a severity of risk.<sup>82</sup> Gastroparesis is not mentioned at all.

108. Similarly, the Novo Nordisk Defendants’ main promotional website for Rybelsus (rybelsus.com) includes a variety of information about the benefits of Rybelsus relating to blood sugar and weight loss, as well as “Important Safety Information”; however, the Novo Nordisk Defendants do not disclose any risks causally associated with gastroparesis within the “Important Safety Information” section or elsewhere on their promotional website.<sup>83</sup>

109. From the date Novo Nordisk received FDA approval to market Rybelsus until the present time, Novo Nordisk made, distributed, marketed, and/or sold Rybelsus without adequate warning to Plaintiff’s prescribing physician(s) and/or Plaintiff that Rybelsus was causally associated with and/or could cause gastroparesis and its sequelae.

110. None of Defendants’ additional advertising or promotional materials warned prescription providers or the general public of the risks of gastroparesis and its sequelae.

111. Defendants knew or should have known of the causal association between the use of GLP-1RAs and the risk of developing gastroparesis and its sequelae. Defendants’ actual and constructive knowledge derived from their clinical studies, case reports, and the medical literature, including the medical literature and case reports referenced in this Complaint.

112. Upon information and belief, Defendants ignored the causal association between

---

<sup>82</sup> Rybelsus prescribing information, available at <http://www.novo-pi.com/rybelsus.pdf> (last visited on 9/20/23).

<sup>83</sup> See Rybelsus.com (last visited on 9/20/23).

the use of GLP-1RAs and the risk of developing gastroparesis and its sequelae.

113. Novo Nordisk's failure to disclose information that they possessed regarding the causal association between the use of GLP-1RAs and the risk of developing gastroparesis and its sequelae, rendered the warnings for Ozempic and Rybelsus inadequate.

114. On information and belief, as a result of Defendants' inadequate warnings, the medical community at large, and Plaintiff's prescribing physician(s) in particular, were not aware that Ozempic and Rybelsus can cause gastroparesis, nor were they aware that "common adverse reactions" listed on the labels might be sequelae of gastroparesis.

115. On information and belief, had Defendants adequately warned Plaintiff's prescribing physician(s) that Ozempic and Rybelsus are causally associated with gastroparesis and its sequelae, then the physician's prescribing decision would have changed by not prescribing Ozempic or Rybelsus, or by monitoring Plaintiff's health for symptoms of gastroparesis and discontinuing Ozempic and Rybelsus when the symptoms first started.

116. By reason of the foregoing acts and omissions, Plaintiff was and still is caused to suffer from gastroparesis and its sequelae, which resulted in severe and personal injuries which are permanent and lasting in nature, physical pain, and mental anguish, including diminished enjoyment of life, as well as the need for lifelong medical treatment, monitoring and/or medications, and fear of developing any of the above-named health consequences.

**FIRST CAUSE OF ACTION**  
**NEGLIGENT FAILURE TO WARN - INADEQUATE WARNING**  
**Pursuant to O.R.C. §2307.01 et seq., and Common Law**

117. Plaintiff repeats, reiterates, and realleges each and every allegation of this Complaint contained in each of the foregoing paragraphs inclusive, with the same force and effect as if more fully set forth herein.

118. Ohio law imposes a duty on producers, manufacturers, distributors, lessors, and sellers of a product to exercise all reasonable care when producing, manufacturing, distributing, leasing, and selling their products.

119. At all times mentioned herein, Defendants designed, researched, manufactured, tested, advertised, promoted, marketed, sold and/or distributed the Rybelsus that were used by Plaintiff.

120. Rybelsus was expected to and did reach the usual consumers, handlers, and persons coming into contact with said product without substantial change in the condition in which it was produced, manufactured, sold, distributed, and marketed by Defendants.

121. At all relevant times, and at the time Rybelsus left Defendants' control, Defendants knew or should have known that Rybelsus were unreasonably dangerous because they did not adequately warn of the risk of gastroparesis and its sequelae, especially when used in the form and manner as provided by Defendants.

122. Despite the fact that Defendants knew or should have known that Rybelsus caused unreasonably dangerous injuries, Defendants continued to market, distribute, and/or sell Rybelsus to consumers, including Plaintiff, without adequate warnings.

123. Despite the fact that Defendants knew or should have known that Rybelsus caused unreasonably dangerous injuries, Defendants continued to market Rybelsus to prescribing physicians, including Plaintiff's prescribing physician(s), without adequate warnings.

124. Defendants knew or should have known that consumers such as Plaintiff would foreseeably suffer injury as a result of their failure to provide adequate warnings, as set forth herein.

125. At all relevant times, given its increased safety risks, Rybelsus was not fit for the

ordinary purpose for which it was intended.

126. At all relevant times, given its increased safety risks, Rybelsus did not meet the reasonable expectations of an ordinary consumer, particularly Plaintiff.

127. Defendants had a duty to exercise reasonable care in the designing, researching, testing, manufacturing, marketing, supplying, promotion, advertising, packaging, sale, and/or distribution of Rybelsus into the stream of commerce, including a duty to assure that the product would not cause users to suffer unreasonable, dangerous injuries, such as gastroparesis and its sequelae.

128. At all relevant times, Plaintiff was using Rybelsus for the purposes and in a manner normally intended—namely, as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus.

129. The Rybelsus designed, researched, manufactured, tested, advertised, promoted, marketed, sold, and distributed by Defendants was defective due to inadequate warnings or instructions, as Defendants knew or should have known that these products created a risk of serious and dangerous injuries, including gastroparesis and its sequelae, as well as other severe and personal injuries which are permanent and lasting in nature, and Defendants failed to adequately warn of said risk.

130. The Rybelsus designed, researched, manufactured, tested, advertised, promoted, marketed, sold, and distributed by Defendants was defective due to inadequate post-marketing surveillance and/or warnings because, after Defendants knew or should have known of the risks of serious side effects, including gastroparesis and its sequelae, as well as other severe and permanent health consequences from Rybelsus, they failed to provide adequate warnings to users and/or prescribers of the product, and continued to improperly advertise, market and/or promote

their product.

131. The label for Rybelsus was inadequate because they did not warn and/or adequately warn of all possible adverse side effects causally associated with the use of Rybelsus, including the increased risk of gastroparesis and its sequelae.

132. The label for Rybelsus was inadequate because they did not warn and/or adequately warn that Rybelsus had not been sufficiently and/or adequately tested for safety risks, including gastroparesis and its sequelae.

133. The label Rybelsus was inadequate because they did not warn and/or adequately warn of all possible adverse side effects concerning the failure and/or malfunction of Rybelsus.

134. The labels for Rybelsus was inadequate because they did not warn and/or adequately warn of the severity and duration of adverse effects, as the warnings given did not accurately reflect the symptoms or severity of the side effects.

135. Communications made by Defendants to Plaintiff and Plaintiff's prescribing physician(s) were inadequate because Defendants failed to warn and/or adequately warn of all possible adverse side effects causally associated with the use of Rybelsus, including the increased risk of gastroparesis and its sequelae.

136. Communications made by Defendants to Plaintiff and Plaintiff's prescribing physician(s) were inadequate because Defendants failed to warn and/or adequately warn that Rybelsus had not been sufficiently and/or adequately tested for safety risks, including gastroparesis and its sequelae.

137. Plaintiff had no way to determine the truth behind the inadequacies of Defendants' warnings as identified herein, and Plaintiff's reliance upon Defendants' warnings was reasonable.

138. Plaintiff's prescribing physician(s) had no way to determine the truth behind the

inadequacies of Defendants' warnings as identified herein, and his/her/their reliance upon Defendants' warnings was reasonable.

139. Upon information and belief, had Plaintiff's prescribing physician(s) been warned of the increased risks of gastroparesis and its sequelae, which are causally associated with Rybelsus, then the prescribing physician would not have prescribed Rybelsus and/or would have provided Plaintiff with adequate warnings regarding the dangers of Rybelsus so as to allow Plaintiff to make an informed decision regarding Plaintiff's use of Rybelsus.

140. Upon information and belief, had Plaintiff's prescribing physician(s) been warned that Rybelsus had not been sufficiently and/or adequately tested for safety risks, including gastroparesis and its sequelae, the prescribing physician would not have prescribed Rybelsus and/or would have provided Plaintiff with adequate warnings regarding the lack of sufficient and/or adequate testing of Rybelsus so as to allow Plaintiff to make an informed decision regarding Plaintiff's use of Rybelsus.

141. If Plaintiff had been warned of the increased risks of gastroparesis and its sequelae, which are causally associated with Rybelsus, then Plaintiff would not have used Rybelsus and/or suffered from gastroparesis and its sequelae.

142. If Plaintiff had been warned that Rybelsus had not been sufficiently and/or adequately tested for safety risks, including gastroparesis and its sequelae, then Plaintiff would not have used Rybelsus and/or suffered gastroparesis and its sequelae.

143. If Plaintiff had been warned of the increased risks of gastroparesis and its sequelae, which is causally associated with Rybelsus, then Plaintiff would have informed Plaintiff's prescribers that Plaintiff did not want to take Rybelsus.

144. Upon information and belief, if Plaintiff had informed Plaintiff's prescribing

physician(s) that Plaintiff did not want to take Rybelsus due to the risks of gastroparesis and its sequelae, or the lack of adequate testing for safety risks, then Plaintiff's prescribing physician(s) would not have prescribed Rybelsus.

145. By reason of the foregoing, Defendants have become liable to Plaintiff for the designing, marketing, promoting, distribution and/or selling of an unreasonably dangerous product, Rybelsus.

146. Defendants designed, researched, manufactured, tested, advertised, promoted, marketed, sold, and distributed a defective product which created an unreasonable risk to the health of consumers and to Plaintiff in particular, and Defendants are therefore liable for the injuries sustained by Plaintiff.

147. Defendants' inadequate warnings for Rybelsus were acts that amount to willful, wanton, and/or reckless conduct by Defendants.

148. Said inadequate warnings for Defendants' drug Rybelsus was a substantial factor in causing Plaintiff's injuries.

149. As a result of the foregoing acts and omissions, Plaintiff was caused to suffer serious and dangerous injuries, including gastroparesis and its sequelae, which resulted in other severe and personal injuries which are permanent and lasting in nature, including physical pain, mental anguish, diminished enjoyment of life, as well as the need for lifelong medical treatment, monitoring and/or medications, and fear of developing any of the above-named health consequences.

150. As a result of the foregoing acts and omissions Plaintiff did incur medical, health, incidental, and related expenses, and requires and/or will require more health care and services. Plaintiff is informed and believes and further alleges that Plaintiff will require future medical

and/or hospital care, attention, and services.

**SECOND CAUSE OF ACTION  
STRICT PRODUCTS LIABILITY  
Pursuant to O.R.C. §2307.01 et seq., and Common Law**

151. Plaintiff repeats, reiterates, and realleges each and every allegation of this Complaint contained in each of the foregoing paragraphs inclusive, with the same force and effect as if more fully set forth herein.

152. At all relevant times, Defendants engaged in the business of researching, testing, developing, manufacturing, labeling, marketing, selling, inspecting, handling, storing, distributing, and/or promoting Rybelsus and placed it into the stream of commerce in a defective and unreasonably dangerous condition. These actions were under the ultimate control and supervision of Defendants.

153. Defendants, as manufacturers and distributors of pharmaceutical drugs, are held to the level of knowledge of an expert in the field, and further, Defendants knew or should have known that warnings and other clinically relevant information and data that it distributed regarding the risks associated with the use of Rybelsus were inadequate.

154. Plaintiff did not have the same knowledge as Defendants, and no adequate warning or other clinically relevant information and data was communicated to Plaintiff or to Plaintiff's treating physicians.

155. Defendants had a duty to provide adequate warnings and instructions for Rybelsus, to use reasonable care to design a product that is not unreasonably dangerous to users, and to adequately understand, test, and monitor its product.

156. Defendants had a continuing duty to provide consumers, including Plaintiff and Plaintiff's physicians, with warnings and other clinically relevant information and data regarding

the risks and dangers associated with Rybelsus as it became or could have become available to Defendants.

157. Defendants marketed, promoted, distributed, and sold an unreasonably dangerous and defective prescription drug, Rybelsus, to health care providers empowered to prescribe and dispense Rybelsus to consumers, including Plaintiff, without adequate warnings and other clinically relevant information and data. Through both omission and affirmative misstatements, Defendants misled the medical community about the risk and benefit balance of Rybelsus, which resulted in injury to Plaintiff.

158. Defendants knew or should have known through testing, scientific knowledge, advances in the field, published research, and/or its own post-marketing studies, that Rybelsus created a risk of serious gastrointestinal injuries, including gastroparesis and its sequelae.

159. Despite the fact that Defendants knew or should have known that Rybelsus caused unreasonable and dangerous side effects, it continued to promote and market Rybelsus without stating that there existed safer and more or equally effective alternative drug products and/or providing adequate clinically relevant information and data.

160. Defendants knew or should have known that consumers, Plaintiff specifically, would foreseeably and needlessly suffer injury as a result of Defendants' failures.

161. The Rybelsus supplied to Plaintiff by Defendants was defective, unreasonably dangerous, and had inadequate warnings or instructions at the time it was sold, and Defendants also acquired additional knowledge and information confirming the defective and unreasonably dangerous nature of Rybelsus. Despite this knowledge and information, Defendants failed and neglected to issue adequate warnings that Rybelsus causes serious and potentially irreversible gastrointestinal injuries.

162. Defendants' failure to provide adequate warnings or instructions rendered Rybelsus unreasonably dangerous in that it failed to perform as safely as an ordinary patient, prescriber, and/or other consumer would expect when used as intended and/or in a manner reasonably foreseeable by Defendants, and in that the risk of danger outweighs the benefits.

163. Defendants failed to provide timely and adequate warnings to physicians and consumers, including Plaintiff and to Plaintiff's intermediary physicians, in the following ways:

a. Defendants failed to include adequate warnings and/or provide adequate clinically relevant information and data that would alert Plaintiff and Plaintiff's physicians to the dangerous risks of Rybelsus including, among other things, gastroparesis;

b. Defendants failed to provide adequate post-marketing warnings and instructions (including regarding the increasing risk with long-term usage) after Defendants knew or should have known of the significant risks of, among other things, gastroparesis; and

c. Defendants continued to promote and sell Rybelsus, even after they knew or should have known of the unreasonable risks of gastrointestinal injuries from the drug.

164. Defendants had an obligation to provide Plaintiff and Plaintiff's physicians with adequate clinically relevant information and data and warnings regarding the adverse health risks associated with exposure to Rybelsus, and/or that there existed safer and more or equally effective alternative drug products, treatment options, and/or delivery mechanisms.

165. By failing to provide Plaintiff and Plaintiff's physicians with adequate clinically relevant information, data, and warnings regarding the adverse health risks associated with exposure to Rybelsus, and/or that there existed safer and more or equally effective alternative drug products, Defendants breached their duty of reasonable care and safety.

166. By failing to adequately test and research harms associated with Rybelsus, and by failing to provide appropriate warnings and instructions about Rybelsus use, patients and the medical community—including Plaintiff and Plaintiff's prescribing doctors—were inadequately informed about the true risk-benefit profile of Rybelsus and were not sufficiently aware that

serious gastrointestinal injuries were associated with use of Rybelsus. Nor were the medical community, patients, patients' families, or regulators appropriately informed that gastrointestinal injuries might be a side effect of Rybelsus and should or could be reported as an adverse event.

167. The Rybelsus designed, researched, manufactured, tested, advertised, promoted, marketed, sold and distributed by Defendants was defective due to inadequate post-marketing surveillance and/or warnings because, even after Defendants knew or should have known of the risks and severe and permanent gastrointestinal injuries from receiving Rybelsus, they failed to provide adequate warnings to users or consumers of the product and continued to improperly advertise, market, and/or promote Rybelsus.

168. Rybelsus is defective and unreasonably dangerous to Plaintiff and other consumers regardless of whether Defendants had exercised all possible care in its preparation and sale.

169. The foreseeable risk of serious gastrointestinal injuries caused by Rybelsus could have been reduced or avoided by Plaintiff, prescribers, and/or other consumers if Defendants had provided reasonable instructions or warnings of these foreseeable risks of harm.

170. Defendants' actions described above were performed willfully, intentionally, and with reckless disregard of the health and safety of Plaintiff and the general public.

171. As a direct and proximate result of Defendants' conduct, including the inadequate warnings, dilution or lack of information, lack of adequate testing and research, and the defective and dangerous nature of Rybelsus, Plaintiff suffered bodily injury and resulting pain and suffering, disability, mental anguish, loss of capacity for the enjoyment of life, expense of medical and nursing care and treatment, loss of earnings, loss of ability to earn money and other economic losses, and aggravation of previously existing conditions. The losses are either permanent or continuing, and Plaintiff will suffer the losses in the future.

**THIRD CAUSE OF ACTION  
PUNITIVE DAMAGES**

172. Plaintiff repeats, reiterates, and realleges each and every allegation of this Complaint contained in each of the foregoing paragraphs inclusive, with the same force and effect as if more fully set forth herein.

173. Defendants' acts and omissions constituted oppression, fraud, malice, and/or recklessness and were done with advance knowledge, conscious disregard of the safety of others, and/or ratification by Defendants' officers, directors, and/or managing agents.

174. Defendants' actions amounted to actual malice or reckless indifference to the likelihood of harm associated with its acts and omissions.

175. Defendants misled both the medical community and the public, including Plaintiff and Plaintiff's physicians, by making false, misleading, or incomplete representations about the safety and effectiveness of Rybelsus and by failing to provide adequate instructions and training concerning its use.

176. Defendants marketed, promoted, distributed, and sold an unreasonably dangerous and defective prescription drug to healthcare providers empowered to prescribe and dispense Rybelsus to consumers, including Plaintiff, without adequate warnings and other clinically relevant information and data and misled the medical community about the need for and the risk-benefit balance of Rybelsus, which resulted in injury to Plaintiff.

177. Defendants downplayed, understated, and/or disregarded its knowledge of the serious and permanent side effects and risks associated with the use of Rybelsus despite available information demonstrating that the drug could interfere with health.

178. Defendants were or should have been in possession of evidence demonstrating that Rybelsus use could interfere with gastrointestinal processes and digestion, including gastroparesis.

Nevertheless, Defendants continued to market Rybelsus by providing false and misleading information regarding its safety and effectiveness.

179. Defendants failed to provide warnings that would have dissuaded health care professionals from using Rybelsus, thus preventing health care professionals, including Plaintiff's prescribing physician, and consumers, including Plaintiff, from weighing the true risks against the benefits of using Rybelsus.

180. Defendants knew or should have known that consumers, and Plaintiff specifically, would foreseeably and needlessly suffer injury as a result of Rybelsus's negligent failure to warn, negligent design, and/or negligent marketing, and consciously, deliberately and callously disregarded that knowledge in favor of maximizing sales and profits.

181. As a direct and proximate result of Defendants' acts and omissions, Plaintiff suffers from gastrointestinal injuries caused by Plaintiff receiving Rybelsus.

182. As a result of Plaintiff's injuries, Plaintiff has endured substantial pain and suffering, has incurred significant expenses for medical care, and will remain economically challenged and emotionally harmed.

183. Plaintiff has suffered and will continue to suffer economic loss and emotional harm.

184. Defendants' actions were performed willfully, intentionally, and with reckless disregard for the rights of Plaintiff and the public.

185. Plaintiff's injuries and damages are severe, permanent, and will continue into the future. As a result, Plaintiff seeks actual and punitive damages from Defendants.

186. Defendants' conduct was committed with knowing, conscious, deliberate, or reckless disregard for the rights and safety of consumers, including Plaintiff, thereby entitling

Plaintiff to punitive damages in an amount appropriate to punish the Defendants and deter them and those similarly situated from similar conduct in the future.

Consequently, Defendants are liable for punitive damages in an amount to be determined by the jury.

### **PRAYER FOR RELIEF**

WHEREFORE, Plaintiff demands judgment against Defendants on each of the above-referenced claims and Causes of Action and as follows:

1. Awarding compensatory damages to Plaintiff for past and future damages, including but not limited to pain and suffering for severe and permanent personal injuries sustained by Plaintiff, health care costs, medical monitoring, together with interest and costs as provided by law;
2. Punitive and/or exemplary damages for the wanton, willful, fraudulent, reckless acts of Defendants, who demonstrated a complete disregard and reckless indifference for the safety and welfare of the general public and to Plaintiff in an amount sufficient to punish Defendants and deter future similar conduct;
3. Awarding Plaintiff the costs of these proceedings; and
4. Such other and further relief as this Court deems just and proper.

### **DEMAND FOR JURY TRIAL**

Plaintiff hereby demands trial by jury as to all issues.

Dated: March 15, 2024

s/Lisa Ann Gorshe  
Lisa Ann Gorshe MN #029522X  
Stacy K. Hauer MN #317093  
JOHNSON BECKER, PLLC  
444 Cedar Street, Suite 1800  
St. Paul, MN 55101  
Tel: 612-436-1800  
Fax: 612-436-1801  
[lgorshe@johnsonbecker.com](mailto:lgorshe@johnsonbecker.com)  
[shauer@johnsonbecker.com](mailto:shauer@johnsonbecker.com)

*Attorneys for Plaintiffs*